ZURA BIO LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.19 USD | +19.27% |
|
+12.83% | +11.13% |
| May. 10 | Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating | MT |
| May. 09 | Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 374M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -59M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-11.6
x | P/E ratio 2025 * |
-7.32
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.2% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.58% | ||
| 1 week | +12.83% | ||
| Current month | +21.55% | ||
| 1 month | +70.72% | ||
| 3 months | +33.08% | ||
| 6 months | +21.83% | ||
| Current year | +11.13% |
1 week
4.52
6.20
1 month
3.136.20
Current year
2.006.20
1 year
2.0013.00
3 years
2.0037.55
5 years
2.0037.55
10 years
2.0037.55
| Managers | Title | Age | Since |
|---|---|---|---|
Someit Sidhu
FOU | Founder | 34 | 22-01-17 |
Robert Lisicki
CEO | Chief Executive Officer | 57 | Jan. 07 |
Verender Badial
DFI | Director of Finance/CFO | 51 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Amit Munshi
CHM | Chairman | 56 | 23-02-28 |
Steven Schoch
BRD | Director/Board Member | 64 | 23-02-28 |
Sandeep Kulkarni
BRD | Director/Board Member | 43 | 22-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 5.19 | +0.58% | 128 198 |
| 24-05-16 | 6 | +15.61% | 397,224 |
| 24-05-15 | 5.19 | +0.58% | 128,198 |
| 24-05-14 | 5.16 | +7.72% | 256,541 |
| 24-05-13 | 4.79 | +2.35% | 162,379 |
End-of-day quote Nasdaq, May 14, 2024
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6
USD
Average target price
17.8
USD
Spread / Average Target
+196.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.13% | 374M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.12% | 22.28B | |
| -11.90% | 22.41B | |
| -5.52% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- ZURA Stock
